LEGN — Legend Biotech Income Statement
0.000.00%
Last trade - 00:00- $3.53bn
- $3.00bn
- $1.03bn
Annual income statement for Legend Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F/A | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 68.8 | 117 | 285 | 627 | 1,029 |
| Cost of Revenue | |||||
| Gross Profit | — | 51.6 | 141 | 393 | 621 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 469 | 554 | 813 | 937 | 1,165 |
| Operating Profit | -400 | -437 | -528 | -310 | -137 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -407 | -446 | -520 | -158 | -283 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -404 | -446 | -518 | -177 | -297 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -404 | -446 | -518 | -177 | -297 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -404 | -446 | -518 | -177 | -297 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.43 | -1.4 | -1.47 | -0.476 | -0.805 |